安洛替尼作为肝细胞癌术后复发高危患者辅助治疗的有效性和安全性。

Jianguo Wang, Xiaonan Xiang, Zhixiong Shi, Hui Zhang, Quanbao Zhang, Zhikun Liu, Guangjie Zhao, Chuanxing Wu, Qiang Wei, Lin Zhong, Zhengxin Wang, Guoyue Lv, Shusen Zheng, Xiao Xu
{"title":"安洛替尼作为肝细胞癌术后复发高危患者辅助治疗的有效性和安全性。","authors":"Jianguo Wang,&nbsp;Xiaonan Xiang,&nbsp;Zhixiong Shi,&nbsp;Hui Zhang,&nbsp;Quanbao Zhang,&nbsp;Zhikun Liu,&nbsp;Guangjie Zhao,&nbsp;Chuanxing Wu,&nbsp;Qiang Wei,&nbsp;Lin Zhong,&nbsp;Zhengxin Wang,&nbsp;Guoyue Lv,&nbsp;Shusen Zheng,&nbsp;Xiao Xu","doi":"10.21147/j.issn.1000-9604.2023.04.06","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Hepatocellular carcinoma (HCC) has a high rate of postoperative recurrence and lacks an effective treatment to prevent recurrence. This study aims to investigate the efficacy and safety of anlotinib in postoperative adjuvant therapy for HCC patients with high-risk recurrence factors.</p><p><strong>Methods: </strong>For this multicenter, retrospective study, we recruited 63 HCC patients who received either anlotinib (n=27) or transcatheter arterial chemoembolization (TACE) (n=36) from six research centers in China between March 2019 and October 2020. The primary endpoint was disease-free survival (DFS) and the secondary endpoints were overall survival (OS) and safety.</p><p><strong>Results: </strong>In this study, the median follow-up time was 25.9 and 26.8 months in the anlotinib and TACE groups, respectively. There was no significant difference in the median DFS between the anlotinib [26.8 months, 95% confidence interval (95% CI): 6.8-NE] and TACE groups (20.6 months, 95% CI: 8.4-NE). The 12-month OS rates in the anlotinib and TACE groups were 96.3% and 97.2%, respectively. In the anlotinib group, 19 of 27 patients (70.4%) experienced treatment-emergent adverse events, with the most common events (≥10%) being hypertension (22.2%) and decreased platelet count (22.2%).</p><p><strong>Conclusions: </strong>The results indicate that anlotinib, as a new, orally administered tyrosine kinase inhibitor, has the same efficacy as TACE, and side effects can be well controlled.</p>","PeriodicalId":9830,"journal":{"name":"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu","volume":"35 4","pages":"399-407"},"PeriodicalIF":0.0000,"publicationDate":"2023-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485915/pdf/cjcr-35-4-399.pdf","citationCount":"0","resultStr":"{\"title\":\"Efficacy and safety of anlotinib as an adjuvant therapy in hepatocellular carcinoma patients with a high risk of postoperative recurrence.\",\"authors\":\"Jianguo Wang,&nbsp;Xiaonan Xiang,&nbsp;Zhixiong Shi,&nbsp;Hui Zhang,&nbsp;Quanbao Zhang,&nbsp;Zhikun Liu,&nbsp;Guangjie Zhao,&nbsp;Chuanxing Wu,&nbsp;Qiang Wei,&nbsp;Lin Zhong,&nbsp;Zhengxin Wang,&nbsp;Guoyue Lv,&nbsp;Shusen Zheng,&nbsp;Xiao Xu\",\"doi\":\"10.21147/j.issn.1000-9604.2023.04.06\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Hepatocellular carcinoma (HCC) has a high rate of postoperative recurrence and lacks an effective treatment to prevent recurrence. This study aims to investigate the efficacy and safety of anlotinib in postoperative adjuvant therapy for HCC patients with high-risk recurrence factors.</p><p><strong>Methods: </strong>For this multicenter, retrospective study, we recruited 63 HCC patients who received either anlotinib (n=27) or transcatheter arterial chemoembolization (TACE) (n=36) from six research centers in China between March 2019 and October 2020. The primary endpoint was disease-free survival (DFS) and the secondary endpoints were overall survival (OS) and safety.</p><p><strong>Results: </strong>In this study, the median follow-up time was 25.9 and 26.8 months in the anlotinib and TACE groups, respectively. There was no significant difference in the median DFS between the anlotinib [26.8 months, 95% confidence interval (95% CI): 6.8-NE] and TACE groups (20.6 months, 95% CI: 8.4-NE). The 12-month OS rates in the anlotinib and TACE groups were 96.3% and 97.2%, respectively. In the anlotinib group, 19 of 27 patients (70.4%) experienced treatment-emergent adverse events, with the most common events (≥10%) being hypertension (22.2%) and decreased platelet count (22.2%).</p><p><strong>Conclusions: </strong>The results indicate that anlotinib, as a new, orally administered tyrosine kinase inhibitor, has the same efficacy as TACE, and side effects can be well controlled.</p>\",\"PeriodicalId\":9830,\"journal\":{\"name\":\"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu\",\"volume\":\"35 4\",\"pages\":\"399-407\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-08-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485915/pdf/cjcr-35-4-399.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21147/j.issn.1000-9604.2023.04.06\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21147/j.issn.1000-9604.2023.04.06","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的:肝细胞癌(HCC)术后复发率高,缺乏有效的预防复发治疗。本研究旨在探讨安洛替尼在有高危复发因素的HCC患者术后辅助治疗中的疗效和安全性。方法:在这项多中心回顾性研究中,我们从2019年3月至2020年10月期间在中国的六个研究中心招募了63名接受anlotinib (n=27)或经导管动脉化疗栓塞(TACE) (n=36)的HCC患者。主要终点是无病生存期(DFS),次要终点是总生存期(OS)和安全性。结果:本研究中,anlotinib组和TACE组的中位随访时间分别为25.9个月和26.8个月。anlotinib组[26.8个月,95%可信区间(95% CI): 6.8-NE]和TACE组(20.6个月,95% CI: 8.4-NE)的中位DFS无显著差异。anlotinib组和TACE组的12个月OS率分别为96.3%和97.2%。在anlotinib组中,27例患者中有19例(70.4%)出现了治疗中出现的不良事件,最常见的事件(≥10%)是高血压(22.2%)和血小板计数下降(22.2%)。结论:安洛替尼作为一种新型口服酪氨酸激酶抑制剂,其疗效与TACE相当,且副作用控制良好。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Efficacy and safety of anlotinib as an adjuvant therapy in hepatocellular carcinoma patients with a high risk of postoperative recurrence.

Objective: Hepatocellular carcinoma (HCC) has a high rate of postoperative recurrence and lacks an effective treatment to prevent recurrence. This study aims to investigate the efficacy and safety of anlotinib in postoperative adjuvant therapy for HCC patients with high-risk recurrence factors.

Methods: For this multicenter, retrospective study, we recruited 63 HCC patients who received either anlotinib (n=27) or transcatheter arterial chemoembolization (TACE) (n=36) from six research centers in China between March 2019 and October 2020. The primary endpoint was disease-free survival (DFS) and the secondary endpoints were overall survival (OS) and safety.

Results: In this study, the median follow-up time was 25.9 and 26.8 months in the anlotinib and TACE groups, respectively. There was no significant difference in the median DFS between the anlotinib [26.8 months, 95% confidence interval (95% CI): 6.8-NE] and TACE groups (20.6 months, 95% CI: 8.4-NE). The 12-month OS rates in the anlotinib and TACE groups were 96.3% and 97.2%, respectively. In the anlotinib group, 19 of 27 patients (70.4%) experienced treatment-emergent adverse events, with the most common events (≥10%) being hypertension (22.2%) and decreased platelet count (22.2%).

Conclusions: The results indicate that anlotinib, as a new, orally administered tyrosine kinase inhibitor, has the same efficacy as TACE, and side effects can be well controlled.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信